HeartBeam, Inc. is at a critical inflection point, launching its FDA-cleared cable-free ambulatory 12-lead ECG device following years of R&D investment but reporting no revenue as of 2025. The company hinges its growth on limited 2026 market entry focused on concierge and preventive cardiology practices, with expansion planned into heart attack detection and extended wear patches. Despite robust clinical validation and patent protections underlying its unique technology, HeartBeam operates with continued losses and negative cash flows, needing successful adoption and further financing to sustain its operations. Key value drivers include future AI-based longitudinal cardiac monitoring capabilities expected to differentiate it from competitors in telehealth and cardiac diagnostics.